Because of a lapse in government funding, the information on this website may not be up to date transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

American Society of Clinical Oncology (ASCO) Recognizes TCGA’s Importance in the Past Decade and in Tumor Biology

April 13, 2015, by Emma J. Spaulding, M.P.H.

The Cancer Genome Atlas (TCGA) was identified as an important advance in the past decade of research by the American Society of Clinical Oncology (ASCO). The article, "Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology" cites TCGA as the first and most comprehensive undertaking of its kind and states that this research is providing essential data that can help to improve patient outcomes.

TCGA’s Pan-Cancer research was named as a "Top Advance in Tumor Biology" because it establishes that tumors from the same tissue of origin may be different from each other in important ways. This research may eventually help patients be matched to a drug targeted to their cancer subtype, which is an important component in precision medicine.

< Older Post

Researchers use Modified CRISPR Systems to Modulate Gene Expression on a Genomic Scale

Newer Post >

Researcher Interview: Elaine Mardis

Featured Posts